Radioactive decay of radioisotopes is a integral to nuclear medicine. Molybdenum-99 (Mo-99), a precursor of the radioisotope, Technetium-99m, is used for ~80% of all nuclear imaging procedures. It is produced in specific nuclear reactors, with recent improvements in cyclotron accelerator production methods, and thus has cost and availability issues. Similar production facilities are used for targeted alpha therapy radioisotopes, an emerging field showing significant promise, but there are frequent complaints that supply problems are delaying research progress in this exciting field.

We will specialize in laser development, for radioisotope production.

Bringing nuclear diagnosis and therapy isotopes to your home town.

Radioisotope production facilities such as nuclear reactors and particle accelerators (e.g. cyclotrons), have constraints that prevent them from being deployed widely and affordably. The average age of reactors producing medical isotopes exceeds 40 years.

There is a very complex supply chain for the production of Molybdenum-99, all constrained by a very tight timeline enforced by the 66.02 hour half-life of Molybdenum-99 and the 6.02 hour half-life of Technetium-99m.  Any manufacturing or transportation delays can result in significant shortages during which radiologists may be forced to scan and diagnose patients prepped for imaging with less than the recommended dose.

Boutique manufacturing is the ideal that our laser technology makes possible. Even though single dose production in the radiotherapy facility that needs it, when it needs it, will be technologically possible, QC requirements will mean that, in practice, it will be done at the small regional level.

Contact us to find out more.